Narayanan Sumana, Attwood Kristopher, Gabriel Emmanuel, Nurkin Steven
Department of Surgical Oncology, Mount Sinai Medical Center, Miami Beach, Florida.
Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, New York.
J Surg Res. 2020 Jul;251:220-227. doi: 10.1016/j.jss.2020.01.019. Epub 2020 Mar 12.
Controversy exists regarding the ability of neoadjuvant chemoradiation (nCR) to diminish lymph node yield (LNY) and how that relationship is influenced by tumor response in patients undergoing proctectomy for locally advanced rectal cancer.
The National Cancer Database was used to identify patients with rectal adenocarcinomas from 2004 to 2014. Patients that received nCR were compared with those that underwent surgery alone. LNY was stratified into <12 and ≥12 groups to determine their differences in stage specific overall survival.
Of 56,812 patients 46.5% underwent surgery alone and 53.5% were administered nCR. There were more patients with LNY<12 in the nCR group compared to surgery alone, across all stages (44.1% versus 36.5%, P < 0.001). nCR improved OS regardless of LNY (P < 0.001). Although patients with LNY≥12 had improved overall survival, patients who had a pathologic complete response (pCR) achieved the greatest survival. In patients that did not achieve a pCR, LNY≥12 was a marker of improved OS but LNY did not impact OS in patients that attained pCR (P < 0.001).
Although nCR diminished LNY, LNY≥12 improved OS demonstrating the importance of quality total mesorectal excision. However, LNY did not impact patients that achieved pCR. These patients, who achieved the best OS, demonstrated that tumors' biologic response to nCR had the greatest impact on patient outcomes.
对于新辅助放化疗(nCR)减少局部晚期直肠癌患者行直肠切除术后淋巴结清扫数量(LNY)的能力以及这种关系如何受肿瘤反应影响存在争议。
利用国家癌症数据库识别2004年至2014年的直肠腺癌患者。将接受nCR的患者与仅接受手术的患者进行比较。LNY分为<12个和≥12个两组,以确定它们在特定分期总生存方面的差异。
在56812例患者中,46.5%仅接受手术,53.5%接受nCR。在所有分期中,nCR组LNY<12的患者比仅接受手术的患者更多(44.1%对36.5%,P<0.001)。无论LNY如何,nCR均改善了总生存(P<0.001)。虽然LNY≥12的患者总生存有所改善,但达到病理完全缓解(pCR)的患者生存获益最大。在未达到pCR的患者中,LNY≥12是总生存改善的标志,但LNY对达到pCR的患者的总生存没有影响(P<0.001)。
虽然nCR减少了LNY,但LNY≥12改善了总生存,这表明了高质量直肠系膜全切除术的重要性。然而,LNY对达到pCR的患者没有影响。这些总生存最佳的患者表明,肿瘤对nCR的生物学反应对患者预后影响最大。